Skip to content
NeuroTechGuide

StimCardio raises $30 million for a wrist-worn nerve stimulator for atrial fibrillation

The Los Angeles company will use its Series A to run a pivotal trial of Rhyvive, which stimulates the median nerve to reduce arrhythmia after ablation, and to prepare an FDA De Novo request.

StimCardio Medical closed a $30 million Series A on October 29, led by John Slump’s family office through Metis MedTech, with Catalyst Health Ventures and corporate investors joining. The Los Angeles company is developing Rhyvive, an investigational wristband that stimulates the median nerve to influence the autonomic nervous system, as an add-on to catheter ablation for atrial fibrillation. The device uses a closed loop that also senses body signals.

The company says its randomized, sham-controlled NeuroPulse 1 pilot, published in Heart Rhythm, showed fewer recurrent arrhythmia events with active stimulation. The new money funds the multicenter NeuroPulse 2 pivotal trial and a planned FDA De Novo submission. The device is not yet authorized.

Learn more: Closed-loop systems

Share:XLinkedInBlueskyEmail

More news